Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ophth. Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ophth. Other
    Cyclosporine 0.05% Is More Effective Than Artificial Tears in Relieving and Preventing Dry Eye: Presented at AAO - (DGDispatch)
    Ganciclovir 0.15% Gel More Effective and Better Tolerated Than Acyclovir 3% Ointment in Patients With Herpetic Keratitis: Presented at AAO - (DGDispatch)
    Vascular Endothelial Growth Factor Inhibition Shows Long-Lasting Efficacy in Treating Neovascular Age-Related Macular Degeneration: Presented at AAO - (DGDispatch)
    Pegaptanib Maintains Visual Outcomes in Age-Related Macular Degeneration After Vascular Endothelial Growth Factor Inhibition: Presented at AAO - (DGDispatch)
    Flexible Dosing of Ranibizumab Safe, Maintains Efficacy in Age-Related Macular Degeneration: Presented at AAO - (DGDispatch)

    News archive

     Recent webcasts/CME - Ophth. Other
      Vision Problems in Older Adults, Part 2
      Vision Problems in Older Adults, Part 1
      Update on the Pathophysiology, Molecular Biology, and Treatment of Macular Edema
      Newer Approaches to the Long-Term Management of Dry Eye Disease
      Global Perspectives on Diabetic Retinopathy: More Than Meets the Eye

      Webcasts/CME archive

       Recent cases - Ophth. Other
        Traumatic Dislocation of the Globe into the Maxillary Sinus
        Chronic Granulomatous Disease Presenting as Retinal Mass: A Case Report
        Folic Acid Deficiency Optic Neuropathy: A Case Report
        Heterochromia
        Metastatic Non-Small Cell Lung Cancer Presenting with an Orbital Metastasis: A Case Report

        Cases archive
          




        my personal edition > ophth. other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        New Adverse Ocular Drug Reactions Related to Bisphosphonates, Retinoids, Topiramate, and Cetirizine: Presented at AAO

        By Deanna M Green, PhD

        ANAHEIM, CA -- November 19, 2003 -- Previously unreported visual side effects have now been identified for bisphosphonates, retinoids, topiramate, and cetirizine, according to findings presented here November 16th at the 2003 Annual Meeting of the American Academy of Ophthalmology.

        Medications for a wide range of conditions have been associated with ocular side effects. These adverse reactions must be reported in order to increase physician and patient awareness regarding the potential complications of therapy.

        Rick W Fraunfelder, MD, at the Casey Eye Institute, Portland, Oregon, United States, reported new findings of ocular side effects related to several medications.

        The study included case reports from the World Heath Organization and the National Registry of Drug-Induced Ocular Side Effects. Reports of ocular side effects were also rated according to the likelihood that the adverse reaction was due to the medication.

        Recent reports have indicated for certain that acute-angle closure glaucoma can result from topiramate use. Symptoms included blurred vision and were reported as early as 3-21 days after start of treatment. Myopia and suprachoroidal effusions were also found to occur with this medication. Fortunately, discontinuation of drug leads to resolution of symptoms. Dr. Fraunfelder also noted that "iridectomy does not help, since the event is not due to pupilary block."

        Pamidronate is the first drug proven to cause scleritis. Seventeen cases have been reported, with symptoms occurring 6-48 hours after pamidronate injection. Further analysis has determined that all bisphosphonates cause uveitis, and these events have been shown to resolve after discontinuation of treatment.

        In all, 1,950 ocular side effects have been reported in patients taking the retinoid drug isotretinoin (Accutane). However, only recently was it determined that isotretinoin also causes pseudotumour cerebri (179 reports). Related symptoms do not develop until 2-3 months after treatment. Furthermore, all retinoids appear to cause this same reaction.

        The Registry has also collected data on nine cases of ocular oculogyric crisis that occurred 21 days after treatment with cetirizine (Zyrtec). Notably, eight of the nine reports were paediatric cases. This reaction also subsides with discontinuation of treatment.

        "Recent reports to the National Registry have led to the identification of new ocular adverse drug reactions," concludes Dr. Fraunfelder. He "encourages physicians to report all ocular adverse drug reactions to the National Registry in order to make the Registry more comprehensive and increase overall awareness."


        [Study title: Adverse Ocular Drug Reactions Recently Identified by the National Registry of Drug-Induced Ocular Side Effects. Abstract: PA017]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send